#United States #New York #Baird Medical #microwave ablation #ACS Congress

Baird Medical's Participation at ACS Clinical Congress 2025

Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD), a forerunner in the domain of minimally invasive Microwave Ablation (MWA) technology, has recently wrapped up a highly successful exhibition at the American College of Surgeons (ACS) Clinical Congress 2025. Held from October 5-7, 2025, this event showcased Baird Medical's cutting-edge technology to a diverse audience of medical professionals from around the world.

The ACS Clinical Congress is acclaimed as one of the world's largest gatherings for surgeons, dedicated to the enhancement of surgical techniques and patient care. This year’s congress attracted thousands of participants, emphasizing the global interest in innovative medical solutions. Within this prestigious backdrop, Baird Medical highlighted its advanced MWA systems, which piqued the interest of numerous surgeons spanning a variety of specialties.

At the company's exhibit, live demonstrations captivated attendees, allowing them to engage directly with MWA technology. Surgeons were able to experience firsthand its applications in treating thyroid nodules, breast disease, and a range of other conditions. The overwhelming positive feedback from participants underscored the urgent demand for effective, minimally invasive treatment options in today's healthcare landscape.

One of the key takeaways from the ACS 2025 was the opportunity for Baird Medical to reconnect with notable leaders in surgery and interventional medicine. These fruitful discussions served to reinforce the company's commitment to improving patient care through continual technological advancements. Such collaboration is vital in fostering partnerships and expanding the company's reach in both U.S. and international markets.

Beyond the demonstrations, the ACS Clinical Congress provided a unique platform for Baird Medical to spotlight its ongoing mission: to enhance outcomes for patients via precision-driven solutions and advanced diagnostic tools. Their expertise lies not only in MWA technology but extends to robotic surgical systems and other innovative surgical instruments.

With FDA 510(k) certification, Baird Medical is recognized as a pivotal player in the medical device industry. Their solutions have been implemented in more than 30 reputable hospitals and clinics throughout the United States, including prestigious institutions such as Johns Hopkins Hospital and Weill Cornell Medicine. Furthermore, Baird Medical holds a commanding presence in China, being the market leader in thyroid microwave ablation devices, while actively working towards establishing a commercial footprint in over 20 countries worldwide.

As Baird Medical looks to the future, the emphasis remains on strategic collaborations with leading academic institutions and the evolution of intelligent systems that not only assist with surgical interventions but also proactively contribute to diagnostic and preventative healthcare strategies.

In summary, Baird Medical's robust engagement in the ACS Clinical Congress 2025 highlights its unwavering commitment to pioneering advancements in minimally invasive technologies. The company is poised for growth within the dynamic medical landscape, eager to meet the evolving needs of healthcare professionals and patients alike, thereby transforming surgical practices through innovation.

For more detailed insights into their promising technologies and future endeavors, please refer to Baird Medical’s official communications and press releases.